Association of inflammatory factors with macular edema in branch retinal vein occlusion

JAMA Ophthalmology

Volumn 131, Issue 2, 2013, Pages 160-165

  Noma, Hidetaka ^a   Mimura, Tatsuya ^b   Eguchi, Shuichiro ^c  

^a Tokyo Women s Medical University   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Eguchi Eye Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTRAXIN 3; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN TISSUE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA BLOOD VESSEL OCCLUSION; RETINA FOVEA; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA MACULA HOLE; RETINAL THICKNESS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VITREORETINAL SURGERY; VITREOUS BODY;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAPILLARY PERMEABILITY; CASE-CONTROL STUDIES; CHEMOKINE CCL2; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE PROTEINS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MACULAR EDEMA; MALE; NERVE GROWTH FACTORS; RETINAL VEIN; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; SERPINS; SERUM AMYLOID P-COMPONENT; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VITRECTOMY; VITREOUS BODY;

EID: 84874042612     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamaophthalmol.228     Document Type: Article

References (62)

1. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamoto K, Kiryu J, Honda Y. In vivo evaluation of leukocyte dynamics in retinal ischemia reperfusion injury. Invest Ophthalmol Vis Sci. 1998;39(5):793-800.
2. Scott IU, Ip MS, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-1128.
3. Miyake K, Miyake T, Kayazawa F. Blood-aqueous barrier in eyes with retinal vein occlusion. Ophthalmology. 1992;99(6):906-910.
4. Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K. Visual prognosis and vitreous molecules after vitrectomy for macular edema with branch retinal vein occlusion. Clin Ophthalmol. 2011;5:223-229.
5. Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999;40(8):1808-1812.
6. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J. 2006;20 (2):323-325.
7. Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4(12): e8158. doi:10.1371/journal.pone.0008158.
8. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006;244(3):309-315.
9. Noma H, Funatsu H, Mimura T, Harino S, Eguchi S, Hori S. Pigment epithelium-derived factor and vascular endothelial growth factor in branch retinal vein occlusion with macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248 (11):1559-1565.
10. Noma H, Funatsu H, Mimura T, Eguchi S, Hori S. Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. Am J Ophthalmol. 2011;152(4):669-677.e1. doi:10.1016/j.ajo.2011.04.006.
11. Kaneda S, Miyazaki D, Sasaki S, et al. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci. 2011;52(6):2982-2988.
12. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102(6): 636-641.
13. Latini R, Maggioni AP, Peri G, et al; Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110(16):2349-2354.
14. Breviario F, d'Aniello EM, Golay J, et al. Interleukin-1-inducible genes in endothelial cells: cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem. 1992;267(31):22190-22197.
15. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337-366.
16. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood. 1994;84(10):3483-3493.
17. Introna M, Alles VV, Castellano M, et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996;87 (5):1862-1872.
18. Goodman AR, Levy DE, Reis LF, Vilcek J. Differential regulation of TSG-14 expression in murine fibroblasts and peritoneal macrophages. J Leukoc Biol. 2000; 67(3):387-395.
19. Doni A, Peri G, Chieppa M, et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol. 2003;33(10):2886-2893.
20. Klouche M, Peri G, Knabbe C, et al. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis. 2004;175(2):221-228.
21. Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G. Synergistic transactivation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. EMBO J. 1990;9(13):4467-4475.
22. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111(12):1805-1812.
23. Souza DG, Soares AC, Pinho V, et al. Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol. 2002;160(5):1755-1765.
24. Souza DG, Amaral FA, Fagundes CT, et al. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol. 2009;174(4):1309-1318.
25. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271-282.
26. Otani T, Kishi S. Tomographic assessment of vitreous surgery for diabetic macular edema. Am J Ophthalmol. 2000;129(4):487-494.
27. Saika S, Tanaka T, Miyamoto T, Ohnishi Y. Surgical posterior vitreous detachment combined with gas/air tamponade for treating macular edema associated with branch retinal vein occlusion: retinal tomography and visual outcome. Graefes Arch Clin Exp Ophthalmol. 2001;239(10):729-732.
28. Stefánsson E, Novack RL, Hatchell DL. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 1990;31(2):284-289.
29. Stefánsson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol. 2006;51(4):364-380.
30. Okunuki Y, Usui Y, Katai N, et al. Relation of intraocular concentrations of inflammatory factors and improvement of macular edema after vitrectomy in branch retinal vein occlusion. Am J Ophthalmol. 2011;151(4):610-616.e1. doi:10.1016/j.ajo.2010.09.030.
31. Yamamoto S, Saito W, Yagi F, Takeuchi S, Sato E, Mizunoya S. Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2004;138(6):907-914.
32. Kumagai K, Furukawa M, Ogino N, Uemura A, Larson E. Long-term outcomes of vitrectomy with or without arteriovenous sheathotomy in branch retinal vein occlusion. Retina. 2007;27(1):49-54.
33. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116(1): 73-79.
34. Deban L, Russo RC, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11(4):328-334.
35. Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol. 2000;156(5):1733-1739.
36. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44(5):2155-2162.
37. Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest. 1996;98(9):2018-2026
38. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factorsignals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem. 1999;274(35) 25130-25135.
39. Wu LW, Mayo LD, Dunbar JD, et al. Utilization of distinctsignaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the nduction of endothelial cell proliferation. J Biol Chem. 2000;275(7):5096-5103.
40. OliveraA, Edsall L, Poulton S, Kazlauskas A, Spiegel S. Platelet-derived growth factor-induced activation of sphingosine kinase requires phosphorylation of the PDGF receptor tyrosine residue responsible for binding of PLCy. FASEB J. 1999 13(12)1593-1600.
41. Ghosh S, Baltimore D. Activation in vitro of NF-KB by phosphorylation of its inhibitor IKB. Nature. 1990;344(6267):678-682.
42. MatsusakaT, Fujikawa K, Nishio Y, et al. Transcription factors NF-IL6 and NF-KB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl AcadSci U S A. 1993;90(21):10193- 10197.
43. Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells: essential roles of a variant NF-KB site and p65 homodimers. J Biol Chem. 1995;270 (2):933-943
44. Wrighton CJ, Hofer-Warbinek R, Moll T, Eytner R, Bach FH, de Martin R. Inhibition of endothelial cell activation by adenovirus-mediated expression of IκBα, an inhibitor of the transcription factor NF-KB. J Exp Med. 1996;183(3):1013-1022.
45. Baldwin AS Jr. The NF-KB and IKB proteins: new discoveries and insights. Annu RevImmunol. 1996;14:649-683.
46. MarumoT, Schini-Kerth VB, Fisslthaler B, Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-KB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation. 1997;96(7):2361-2367
47. Boyle EM Jr, Kovacich JC, Canty TG Jr, et al. Inhibition of nuclear factor-KB nuclear ocalization reduces human E-selectin expression and the systemic inflammatory response. Circulation. 1998;98(19)(suppl):II282-II288.
48. Barnes PJ, Karin M. Nuclear factor-KB: a pivotal transcription factor in chronic nflammatory diseases. NEnglJMed. 1997;336(15):1066-1071.
49. Ghosh S, May MJ, Kopp EB. NF-KB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu RevImmunol. 1998;16:225-260
50. Perkins ND. Integrating cell-signalling pathways with NF-KB and IKK function Nat Rev Mol Cell Biol. 2007;8(1):49-62.
51. Carnevale KA, Cathcart MK. Protein kinase C β is required for human monocyte chemotaxis to MCP-1. J Biol Chem. 2003;278(28):25317-25322.
52. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood. 2005;105 (4):1405-1407.
53. Koga J, Matoba T, Egashira K, et al. Soluble Flt-1 genetransferamelioratesneontima formation after wire injury in flt-1 tyrosine kinase-deficient mice. Arterioscler Thromb Vasc Biol. 2009;29(4):458-464.
54. Hao Q, Wang L, Tang H. Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells Am J Physiol Cell Physiol. 2009;296(4):C821-C827
55. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-KB activation in endothelial cells. J Biol Chem. 2001;276(10):7614-7620.
56. Yao JS, Zhai W, Young WL, Yang GY. Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem Biophys Res Commun. 2006;342(4):1396-1404.
57. Basile A, Sica A, d'Aniello E, et al. Characterization of the promoter for the human long pentraxin PTX3: role of NF-KB in tumor necrosis factor - α and interleukin-1 β regulation. JBiolChem. 1997;272(13):8172-8178
58. FerraraN, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18(1):4-25.
59. Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem Soc Trans. 2003;31(pt 1):20-24.
60. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996 16(9):4604-4613.
61. Pagès G, Pouyssegur J. Transcriptional regulation of the vascularendothelial growth factor gene - a concert of activating factors. Cardiovasc Res. 2005;65(3):564-573.
62. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond). 2008;22(1):42-48.